Trial Radar IA | ||
|---|---|---|
Lo studio clinico NCT05377255 per Overdose da oppioidi è completato. Consulti la vista a schede del Radar degli Studi Clinici e gli strumenti di scoperta IA per tutti i dettagli. Oppure, ponga pure una domanda qui. | ||
Un studio corrisponde ai criteri del filtro
Vista a schede
Torna alla ricerca
Emergent BioSolutionsPharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults Fase I 24 Randomizzato In aperto
I dettagli dello studio clinico sono disponibili principalmente in inglese. Tuttavia, Trial Radar IA può essere d'aiuto! Basta cliccare su 'Spiega lo studio' per visualizzare e discutere le informazioni sullo studio nella lingua selezionata.
La sperimentazione clinica NCT05377255 è stata uno studio interventistico di Fase I condotto per esaminare il trattamento per Overdose da oppioidi, attualmente completato. Avviato il 28 marzo 2022, ha previsto l'arruolamento di 24 partecipanti. Sotto la guida di Emergent BioSolutions, si è concluso il 10 maggio 2022. I dati più recenti da ClinicalTrials.gov sono stati aggiornati l'ultima volta il 18 marzo 2024.
Sommario breve
This study will be a Phase 1, single-center, open-label, randomized cross-over study to evaluate the PK of a new AP003 device which delivers two sprays of 4 mg naloxone hydrochloride intranasally.
Descrizione dettagliata
Based on the intended AP003 product presentation there will be two devices in each carton allowing for administration of a total of 16 mg. This study is designed for subjects to receive naloxone therapy either through the AP003 device or through the currently approved NARCAN® nasal spray (4 mg) device (per label), reference therapy. After administration of the therapy patients will be followed by a 48-hour washout pe...Mostra di più
Titolo ufficiale
A Phase 1, Open Label, Randomized Study to Investigate the Pharmacokinetics and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adult Participants
Patologie
Overdose da oppioidiAltri ID dello studio
- EBS-NAR-001
Numero NCT
Data di inizio (effettiva)
2022-03-28
Ultimo aggiornamento pubblicato
2024-03-18
Data di completamento (stimata)
2022-05-10
Arruolamento (previsto)
24
Tipo di studio
Interventistico
FASE
Fase I
Stato
Completato
Parole chiave
NARCAN
Opioid Overdose
Naloxone
Intranasal
Opioid Overdose
Naloxone
Intranasal
Scopo principale
Trattamento
Allocazione
Randomizzato
Modello di intervento
Studio incrociato
Mascheramento
Nessuno (studio in aperto)
Bracci / Interventi
| Gruppo/Braccio di partecipanti | Intervento/Trattamento |
|---|---|
AltroArm 1 Interventional Therapy Subjects will first receive 4 doses of 4 mg each (total: 16 mg) of naloxone through the AP003 device (Arm 1) before the washout period. | 16 mg naloxone AP003 4 doses of 4 mg each (total: 16 mg) of naloxone through the AP003 device 8 mg naloxone NARCAN Nasal Spray 2 doses of 4 mg each (total: 8 mg) of the naloxone through the NARCAN Nasal Spray device |
AltroArm 2 Reference Therapy Subjects will first receive 2 doses of 4 mg each (total: 8 mg) of the naloxone through the NARCAN Nasal Spray device (reference therapy, Arm 2) before the washout period. | 16 mg naloxone AP003 4 doses of 4 mg each (total: 16 mg) of naloxone through the AP003 device 8 mg naloxone NARCAN Nasal Spray 2 doses of 4 mg each (total: 8 mg) of the naloxone through the NARCAN Nasal Spray device |
Esito primario
| Misure di esito | Descrizione della misura | Arco temporale |
|---|---|---|
Mean naloxone plasma concentration AP003 dosing periods. | The mean naloxone plasma concentration during the two AP003 dosing periods. | PK samples taken at various timepoints over the course of Pre-dose and post-dose for 12 hours. |
Mean naloxone plasma concentration Narcan dosing periods | The mean naloxone plasma concentration during the two Narcan dosing periods. | PK samples taken at various timepoints over the course of Pre-dose and post-dose for 12 hours. |
Incidence of treatment emergent adverse events (TEAEs), serious adverse events (SAE) | Incidence of treatment emergent adverse events (TEAEs), serious adverse events (SAE) by treatment thru End of Study Visit (within 7 days after 2nd dose). | Through end of study visit (within 7 days after second dose) |
Incidence of abnormal vital signs | Incidence of abnormal vital signs (heart rate, blood pressure, and respiration rate) by treatment thru End of Study Visit (within 7 days after 2nd dose). | Through end of study visit (within 7 days after second dose) |
Incidence of clinically significant ECG | Incidence of clinically significant ECG by treatment thru End of Study Visit (within 7 days after 2nd dose). | Through end of study visit (within 7 days after second dose) |
Incidence of clinical laboratory changes | Incidence of clinical laboratory changes by treatment thru End of Study Visit (within 7 days after 2nd dose). | Through end of study visit (within 7 days after second dose) |
Incidence of adverse events of special interest (AESI) indicating of nasal irritation | Incidence of adverse events of special interest (AESI) indicating of nasal irritation (erythema, edema, and erosion) by treatment thru End of Study Visit (within 7 days after 2nd dose). | Through end of study visit (within 7 days after second dose) |
Incidence of changes in B-SIT assessment | Incidence of changes in B-SIT assessment within an AP003 period thru End of Study Visit (within 7 days after 2nd dose). | Through end of study visit (within 7 days after second dose) |
Criteri di eleggibilità
Età idonea
Adulto
Età minima
18 Years
Sessi idonei
Tutti
Accetta volontari sani
Sì
Are able to consent and freely provide informed consent.
Females and males 18-55 years of age, inclusive.
Have a body mass index (BMI) less than or equal to 34.0 kg/m2.
Generally healthy, in the opinion of the Investigator, based on medical history, physical examination, vital signs, screening laboratory assessments and 12-lead ECG evaluation.
If female:
Have a negative pregnancy test at Screening (serum pregnancy test) and before dosing at Day -1 (urine pregnancy test)
Female subjects of non-childbearing potential must be:
- Post-menopausal (spontaneous amenorrhea for at least 12 months prior to dosing) with confirmation by documented FSH levels ≥40 mIU/mL; or
- Surgically sterile (bilateral oophorectomy, bilateral salpingectomy, hysterectomy, or tubal ligation) at least 3 months prior to dosing.
Women of childbearing potential who are not planning to be pregnant during the study period and who are using one of the following effective methods of contraception during the study period and for at least 30 days after last study visit:
- Simultaneous use of hormonal contraceptive (e.g. oral, patch, depot injection, implant, vaginal ring, intrauterine device) or non-hormonal intrauterine device for at least 4 weeks prior to dosing (must agree to use the same contraceptive throughout the study) and condom for the male partner.
- Simultaneous use of diaphragm or cervical cap with spermicide and condom for the male partner, started at least 21 days prior to dosing.
- Subjects planning to become pregnant during the study or currently breastfeeding.
- Any acute condition, in the opinion of the Investigator, that is not fully resolved at least 4 weeks prior to baseline.
- Subject has a deviated septum, previous rhinoplasty, abnormal nasal anatomy, other nasal symptoms (i.e., blocked and/or runny nose), or other nasal surgeries (i.e., polyp removal) within 1 year, or needs to use another nasal spray product during study.
- Subject with current upper respiratory infection (URI) or has had URI within 7 days prior to screening.
- Subject has had an episode of epistaxis within 30 days prior screening or has experienced recurrent episodes of epistaxis within 1 year prior to screening.
- Subject has used any prescription or nonprescription drugs/supplements with increased risk of bleeding within 28 days or 5 half-lives (whichever is longer) or complementary and alternative medicines within 28 days before the first dose of study drug with exception of oral contraceptives. All other prescription medications, over-the-counter, and natural health products within 14 days or 5 half-lives prior to the first dosing.
- Subject is currently participating in another clinical study of an investigational drug or has been dosed with any investigational drug within 30 days or 5 half-lives (whichever is longer) of the compound.
Emergent BioSolutionsNessun dato di contatto
1 Centri dello studio in 1 paesi
Florida
Syneos Health Clinical Research Services, Miami, Florida, 33136, United States